Institute for International Research

as of November 17, 2008

Oligo therapeutics manufacturing advisors

• Bob D. Brown, Ph.D., Senior Vice President, Research, Dicerna Pharmaceuticals
• Masad J. Damha, Ph.D., F.C.I.C., James McGill Professor of Chemistry, McGill University, Canada
• Kyle Haraldsen, Business Development Manager, Avecia OligoMedicines
• Aimee L. Jackson, Ph.D., Director, Drug Discovery, Regulus Therapeutics
• Arthur M. Krieg, M.D., Chief Scientific Officer, Research Technology Center, Pfizer
• Tim Lannan, Senior Manager, Global Manufacturing Services, Pfizer Inc
• Michael J. McLean, Ph.D., Chairman, Link Technologies Ltd., United Kingdom
• Lubomir V. Nechev, Ph.D., Director, Process Chemistry, Alnylam Pharmaceuticals
• James Powell, General Manager, Agilent Technologies
• Anthony N. Scozzari, Vice President, Development Chemistry, Isis Pharmaceuticals, Inc.
• G. Susan Srivatsa, Ph.D., President, ElixinPharma
• James D. Thompson, Ph.D., Vice President, Pharmaceutical Development, Quark Pharmaceuticals, Inc.
• Fran Wincott, Ph.D., President, Wincott & Associates, LLC
• Emma Wright, Avecia OligoMedicines
• Tadeusz K. Wyrzykiewicz, Ph.D., Oligonucleotides Supervisor, Girindus America Inc.

Peptide therapeutics manufacturing advisors

• Firoz D. Antia, Ph.D., Executive Director, Chemical & Analytical Development, Palatin Technologies, Inc.
• Jesse Dong, Ph.D., Senior Director, Medicinal Chemistry, IPSEN/Biomeasure, Incorporated
• Christopher P. Holmes, Ph.D., Senior Director, Chemistry, Affymax, Inc.
• Rodney Lax, Director, Business Development, PolyPeptide Laboratories, Inc.
• John P. Mayer, Ph.D., Senior Research Advisor, Eli Lilly and Co.
• Gary F. Musso, Ph.D., President, Musso and Associates LLC

Formulation and delivery advisors

• Paul A. Burke, Ph.D., Executive Director, RNA Therapeutics, Merck & Co., Inc.
• Christopher A. Rhodes, Ph.D., Executive Director, Pharmaceutical Sciences, Amylin Pharmaceuticals, Inc.